• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Oncotarget now publishing two issues a week available in PubMed and other high profile scientific research indexes and archives

Bioengineer by Bioengineer
December 21, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget, a distinguished multidisciplinary bio-medical journal, reassured readers this week that all of its scientific publications are and will continue to be available on PubMed, PubMed Central, ISI/Web of Science: Science Citation Index Expanded, Scopus, Biological Abstracts, BIOSIS Previews, and EMBASE. In cooperation with the National Library of Medicine, Oncotarget is achieving its goal to become the first research journal to submit an entire issue to PubMed just days after online publication.

Oncotarget works closely with all high profile scientific indexes and archives to make scientific results rapidly and widely available to medical field researchers, practitioners, and the general public. In an effort to accelerate indexing processes, it is publishing two issues a week. After assigning page and issue numbers they will appear in PubMed permanently. Volume 8 Issues 31-34 appeared on PubMed last week. Volume 8 Issues 35-36 are being processed by the National Library of Medicine this week.

Oncotarget is a twice-weekly, peer-reviewed, open access bio-medical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. It has published seven volumes, 324 issues since 2010 and is now in its eighth volume. Oncotarget gives every paper published a direct object identifier (DOI) and applies the recommendations of the Committee on Publication Ethics (COPE) to all published works.

"We believe that it is necessary to meet the challenges of the 21st century, which is why our mission endures to be a scholarly journal well known for rapid and wide scale dissemination of esteemed bio-medical research," said The Office of External & Legal Affairs of Oncotarget. "Ultimately, Oncotarget is the journal by scientists for scientists," and "will remain a resource to assist all researchers with their contribution to the progress of science as together we strive to see life without disease."

###

To learn more about Oncotarget, visit oncotarget.com.

About Oncotarget

Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online with a mission to make scientific results rapidly and widely available, to maximize the impact of research through an insightful review, and to eliminate the border between biomedical specialties. Oncotarget fosters applications of basic and clinical science to fight disease. Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Oncotarget strives to see a life without disease.

Media Contact

Ryan James Jessup
[email protected]
202-638-9720

Share12Tweet8Share2ShareShareShare2

Related Posts

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

August 31, 2026
Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

August 31, 2026

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

August 31, 2026

Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

August 31, 2026
Please login to join discussion

POPULAR NEWS

  • β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

    29 shares
    Share 12 Tweet 7
  • Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

    29 shares
    Share 12 Tweet 7
  • KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

    29 shares
    Share 12 Tweet 7
  • Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.